About Strata Oncology
Strata Oncology is a company based in Ann Arbor (United States) founded in 2015 by Scott Tomlins and Dan Rhodes. Strata Oncology has raised $139.15 million across 5 funding rounds from investors including Monashee Investment Management, eLab Ventures and Wellington. The company has 125 employees as of December 31, 2022. Strata Oncology offers products and services including Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score. Strata Oncology operates in a competitive market with competitors including ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others.
- Headquarter Ann Arbor, United States
- Employees 125 as on 31 Dec, 2022
- Founders Scott Tomlins, Dan Rhodes
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$139.15 M (USD)
in 5 rounds
-
Latest Funding Round
$6.15 M (USD), Series C
Nov 08, 2024
-
Investors
Monashee Investment Management
& 9 more
-
Employee Count
125
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Strata Oncology
Strata Oncology offers a comprehensive portfolio of products and services, including Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score.
Predictive method for assessing ADC benefits in cancer therapy.
Algorithm evaluating PD-L1 and tumor factors for immunotherapy efficacy.
People of Strata Oncology
Unlock access to complete
Funding Insights of Strata Oncology
Strata Oncology has successfully raised a total of $139.15M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $6.15 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Strata Oncology
Strata Oncology has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Monashee Investment Management, eLab Ventures and Wellington.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Strata Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Strata Oncology
Investment portfolio details for Strata Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Strata Oncology
Detailed financials for Strata Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Strata Oncology Comparisons
Peer comparison for Strata Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Strata Oncology
Strata Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Provider of test panels for personalized cancer therapies
|
Detailed competitors of Strata Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Strata Oncology
Complete news archive for Strata Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Strata Oncology
Strata Oncology was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Strata Oncology is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Dan Rhodes is the current CEO of Strata Oncology. They have also founded this company.
Strata Oncology is a funded company, having raised a total of $139.15M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Strata Oncology is 125.
Strata Oncology was founded in 2015 in Ann Arbor, United States, within the precision oncology sector. Genetic sequencing services are offered to late-stage cancer patients. Partnerships are established with biopharma companies and healthcare institutions to identify suitable ongoing clinical trials. This approach is used to facilitate patient matching and increase enrollment in precision oncology studies. Operations focus on supporting trial access through data-driven insights.
Strata Oncology's top competitors include Personalis, ImaginAb and OncoDNA.
Strata Oncology offers Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score.
Strata Oncology has 10 investors. Key investors include Monashee Investment Management, eLab Ventures, Wellington, HIGHSIDE Global, and Pfizer Venture Investments.